More than 40 organizations, including the AHA, today urged House and Senate leaders to swiftly pass the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974/H.R. 2212). The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “The CREATES Act is a narrowly targeted, bipartisan, pro-competition and market-based solution to these abuses that cost patients, job-creators and taxpayers billions of dollars each year,” the letter states. “…We thank the bipartisan, bicameral sponsors of this important legislation for the work that they have done to, in the words of FDA Commissioner Scott Gottlieb, ‘end the shenanigans’ by certain brand name companies, and we strongly encourage Congress to pass the CREATES Act without delay.”

Related News Articles

Headline
Hospitals and health systems may apply through Feb. 19 for the 2019 AHA Equity of Care Award, which recognizes organizations participating in the AHA's #…
Headline
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and…
Headline
The American Board of Medical Specialties has released an updated guide to the specialty and subspecialty certifications offered by its 24 member boards.
Headline
The AHA and the Federation of American Hospitals today urged Congress to oppose any legislation that would repeal current law limiting self-referral to…
Headline
A coalition of 40 health care and public health organizations, including the AHA, today urged the Senate to quickly pass the Pandemic and All-Hazards…
Headline
Joseph Miller, vice president of behavioral health care transformation services at Hackensack (N.J.) Meridian Health, will serve as 2019 chair of the AHA's…